Incyte Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
83,147.00
48,481.00
6,531.00
104,222.00
313,142.00
109,493
Depreciation, Depletion & Amortization
29,207.00
41,413.00
44,883.00
58,425.00
52,178.00
54,969
Other Funds
14,786.00
478.00
2,879.00
9,117.00
17,046.00
218,763
Funds from Operations
13,662.00
55,375.00
121,383.00
280,003.00
28,759.00
382,766
Changes in Working Capital
4,482.00
29,119.00
34,847.00
24,753.00
64,229.00
46,539
Net Operating Cash Flow
9,180.00
26,256.00
86,536.00
304,756.00
92,988.00
336,227
Capital Expenditures
4,267.00
27,876.00
26,003.00
120,277.00
111,021.00
Purchase/Sale of Investments
33,130.00
110,563.00
79,007.00
30,645.00
238,957.00
Net Investing Cash Flow
37,397.00
138,439.00
105,010.00
232,488.00
349,978.00
Issuance/Reduction of Debt, Net
217,218.00
265.00
1,699.00
445.00
8,934.00
Net Financing Cash Flow
275,589.00
93,057.00
87,616.00
58,645.00
690,171.00
Net Change in Cash
247,372.00
19,132.00
69,142.00
130,904.00
247,166.00
Free Cash Flow
4,913.00
1,620.00
60,533.00
184,479.00
204,009.00
Net Assets from Acquisitions
-
-
-
142,856.00
-
Change in Capital Stock
73,157.00
92,844.00
86,436.00
49,973.00
716,151.00
Exchange Rate Effect
-
6.00
-
9.00
39.00

About Incyte

View Profile
Address
1801 Augustine Cut-Off
Wilmington Delaware 19803
United States
Employees -
Website http://www.incyte.com
Updated 07/08/2019
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.